BofA cuts target for Vertex Pharmaceuticals stock to USD 667

Published on 10/15/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BofA cut Vertex Pharmaceuticals stock target from USD 672 to USD 667 on October 12, 2026. Second-quarter revenue rose 12.50 percent to USD 3.33 billion.

Analyst reset and upcoming results

BofA cut its Vertex Pharma target from USD 672 to USD 667 on October 12, 2026.
Second-quarter 2026 revenue rose 12.50 percent to USD 3.33 billion.
Vertex Pharma stock traded at EUR 448.35 at 11:02 a.m. CEST at Lang & Schwarz on October 15, 2026.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin am Mikroskop im Labor — Vertex Pharma US92532F1003 dokumentiert eine Forscherin beim Mikroskopieren in dokumentarischer Schwarzweiß-Reportage-Optik im Labor, Illustration mit AI erstellt.

Vertex Pharma stock was at EUR 448.35 at Lang & Schwarz on October 15, 2026, while BofA Securities cut its price target from USD 672 to USD 667 on October 12, 2026, according to Investing.com. The bank kept its Buy rating as it reassessed the cystic fibrosis franchise ahead of the next results.

Target reset tests growth expectations

BofA projected third-quarter Trikafta revenue of USD 2.42 billion, below its USD 2.54 billion consensus comparison. It also forecast USD 688 million from Alyftrek, above the USD 651 million consensus, and USD 68 million from Journavx, versus USD 65 million consensus, according to Investing.com.

Three dates show the transition

On July 6, 2026, Vertex agreed to acquire Crinetics for USD 85.00 per share and approximately USD 10.0 billion in equity value. On August 3, 2026, the company reported second-quarter revenue of USD 3.33 billion, up 12.50 percent year over year. On October 12, 2026, BofA reduced its target to USD 667 from USD 672. The deal terms and results were summarized by Ticker Scout, while the target change was reported by Investing.com.

What does the shift mean for revenue?

The second-quarter report showed net income of USD 1.10 billion and diluted earnings per share of USD 4.31, compared with USD 1.03 billion and USD 3.99 in the same quarter of 2025. Alyftrek revenue reached USD 573.6 million, up 265.80 percent year over year, while Trikafta and Kaftrio revenue fell 2.10 percent to USD 2.50 billion, according to Ticker Scout. The figures show the commercial transition behind the competing forecasts.

Next results arrive November 2

Vertex Pharmaceuticals will report third-quarter 2026 results on November 2, 2026, after the market close, with a conference call scheduled for 4:30 p.m. ET, the company said in its October 7, 2026 release. The date and schedule appear in the Vertex Pharmaceuticals newsroom.